Skip to main content
Erschienen in: Applied Health Economics and Health Policy 5/2011

01.09.2011 | Leading Article

Early assessment of medical technologies to inform product development and market access

A review of methods and applications

verfasst von: Dr Maarten J. Ijzerman, Lotte M. G. Steuten

Erschienen in: Applied Health Economics and Health Policy | Ausgabe 5/2011

Einloggen, um Zugang zu erhalten

Abstract

Worldwide, billions of dollars are invested in medical product development and there is an increasing pressure to maximize the revenues of these investments. That is, governments need to be informed about the benefits of spending public resources, companies need more information to manage their product development portfolios and even universities may need to direct their research programmes in order to maximize societal benefits. Assuming that all medical products need to be adopted by the heavily regulated healthcare market at one point in time, it is worthwhile to look at the logic behind healthcare decision making, specifically, decisions on the coverage of medical products and decisions on the use of these products under competing and uncertain conditions.
With the growing tension between leveraging economic growth through R&D spending on the one hand and stricter control of healthcare budgets on the other, several attempts have been made to apply the health technology assessment (HTA) methodology to earlier stages of technology development and implementation. For instance, horizon scanning was introduced to systematically assess emerging technologies in order to inform health policy. Others have introduced iterative economic evaluation, e.g. economic evaluations in earlier stages of clinical research. However, most of these methods are primarily intended to support governments in making decisions regarding potentially expensive new medical products. They do not really inform biomedical product developers on the probability of return on investment, nor do they inform about the market needs and specific requirements of technologies in development. It is precisely this aspect that increasingly receives attention, i.e. is it possible to use HTA tools and methods to inform biomedical product development and to anticipate further development and market access. Several methods have been used in previous decades, but have never been compiled in a comprehensive review.
The main objective of this article was to provide an overview of previous work and methods in the field of early HTA, and to put these approaches in perspective through a conceptual framework introduced in this paper. A particular goal of the review was to familiarize decision makers with available techniques that can be employed in early-stage decision making, and to identify opportunities for further methodological growth in this emerging field of HTA.
Literatur
1.
Zurück zum Zitat Dorsey ER, de Roulet J, Thompson JP, et al. Funding of US biomedical research, 2003-2008. JAMA 2010 Jan 13; 303(2): 137–43PubMedCrossRef Dorsey ER, de Roulet J, Thompson JP, et al. Funding of US biomedical research, 2003-2008. JAMA 2010 Jan 13; 303(2): 137–43PubMedCrossRef
2.
Zurück zum Zitat Portilla LM, Alving B. Reaping the benefits of biomedical research: partnerships required. Sci Transl Med 2010 Jun 9; 2(35): 35cm17CrossRef Portilla LM, Alving B. Reaping the benefits of biomedical research: partnerships required. Sci Transl Med 2010 Jun 9; 2(35): 35cm17CrossRef
3.
4.
Zurück zum Zitat Melese T, Lin SM, Chang JL, et al. Open innovation networks between academia and industry: an imperative for breakthrough therapies. Nat Med 2009 May 1; 15(5): 502–7PubMedCrossRef Melese T, Lin SM, Chang JL, et al. Open innovation networks between academia and industry: an imperative for breakthrough therapies. Nat Med 2009 May 1; 15(5): 502–7PubMedCrossRef
5.
Zurück zum Zitat Moses H, Martin JB. Academic relationships with industry: a new model for biomedical research. JAMA 2001 Feb 21; 285(7): 933–5PubMedCrossRef Moses H, Martin JB. Academic relationships with industry: a new model for biomedical research. JAMA 2001 Feb 21; 285(7): 933–5PubMedCrossRef
6.
Zurück zum Zitat Chesbrough H, Crowther K. Beyond high tech: early adopters of open innovation in other industries. R&D Management 2006 Jan 1; 36(3): 229–36CrossRef Chesbrough H, Crowther K. Beyond high tech: early adopters of open innovation in other industries. R&D Management 2006 Jan 1; 36(3): 229–36CrossRef
7.
Zurück zum Zitat Hartz S, John J. Public health policy decisions on medical innovations: what role can early economic evaluation play? Health Policy 2009 Feb 1; 89(2): 184–92PubMedCrossRef Hartz S, John J. Public health policy decisions on medical innovations: what role can early economic evaluation play? Health Policy 2009 Feb 1; 89(2): 184–92PubMedCrossRef
8.
Zurück zum Zitat Murphy K, Packer C, Stevens A, et al. Effective early warning systems for new and emerging health technologies: developing an evaluation framework and an assessment of current systems. Int J Technol Assess Health Care 2007 Jun 21; 23(3): 324–30PubMedCrossRef Murphy K, Packer C, Stevens A, et al. Effective early warning systems for new and emerging health technologies: developing an evaluation framework and an assessment of current systems. Int J Technol Assess Health Care 2007 Jun 21; 23(3): 324–30PubMedCrossRef
9.
Zurück zum Zitat Wild C, Langer T. Emerging health technologies: informing and supporting health policy early. Health Policy 2008 Aug 1; 87(2): 160–71PubMedCrossRef Wild C, Langer T. Emerging health technologies: informing and supporting health policy early. Health Policy 2008 Aug 1; 87(2): 160–71PubMedCrossRef
10.
Zurück zum Zitat Hartz S, John J. Contribution of economic evaluation to decision making in early phases of product development: a methodological and empirical review. Int J Technol Assess Health Care 2008 Oct 3; 24(4): 465–72PubMedCrossRef Hartz S, John J. Contribution of economic evaluation to decision making in early phases of product development: a methodological and empirical review. Int J Technol Assess Health Care 2008 Oct 3; 24(4): 465–72PubMedCrossRef
11.
Zurück zum Zitat Chalmers I. Biomedical research: are we getting value for money? Significance 2006 Jan 1: 172–5 Chalmers I. Biomedical research: are we getting value for money? Significance 2006 Jan 1: 172–5
12.
Zurück zum Zitat Cookson R, McDaid D, Maynard A. Wrong SIGN, NICE mess: is national guidance distorting allocation of resources? BMJ 2001 Sep 29; 323(7315): 743–5PubMedCrossRef Cookson R, McDaid D, Maynard A. Wrong SIGN, NICE mess: is national guidance distorting allocation of resources? BMJ 2001 Sep 29; 323(7315): 743–5PubMedCrossRef
13.
Zurück zum Zitat Caro JJ, Nord E, Siebert U, et al. The efficiency frontier approach to economic evaluation of health-care interventions. Health Econ 2010 Sep 1; 19(10): 1117–27PubMedCrossRef Caro JJ, Nord E, Siebert U, et al. The efficiency frontier approach to economic evaluation of health-care interventions. Health Econ 2010 Sep 1; 19(10): 1117–27PubMedCrossRef
14.
Zurück zum Zitat Towse A. Value based pricing, research and development, and patient access schemes: will the United Kingdom get it right or wrong? Br J Clin Pharmacol 2010 Aug 1; 70(3): 360–6PubMedCrossRef Towse A. Value based pricing, research and development, and patient access schemes: will the United Kingdom get it right or wrong? Br J Clin Pharmacol 2010 Aug 1; 70(3): 360–6PubMedCrossRef
15.
Zurück zum Zitat Bianchini D, Zivi A, Sandhu S, et al. Horizon scanning for novel therapeutics for the treatment of prostate cancer. Ann Oncol 2010 Oct 1; 21Suppl. 7: vii43–55PubMedCrossRef Bianchini D, Zivi A, Sandhu S, et al. Horizon scanning for novel therapeutics for the treatment of prostate cancer. Ann Oncol 2010 Oct 1; 21Suppl. 7: vii43–55PubMedCrossRef
16.
Zurück zum Zitat Mortimer D. Modelling downstream effects in the presence of technological change. Pharmacoeconomics 2008; 26(12): 991–1003PubMedCrossRef Mortimer D. Modelling downstream effects in the presence of technological change. Pharmacoeconomics 2008; 26(12): 991–1003PubMedCrossRef
17.
Zurück zum Zitat Püntmann I, Schmacke N, Melander A, et al. EVITA: a tool for the early EValuation of pharmaceutical Innovations with regard to Therapeutic Advantage. BMC Clin Pharmacol 2010 Mar 16; 10: 5PubMedCrossRef Püntmann I, Schmacke N, Melander A, et al. EVITA: a tool for the early EValuation of pharmaceutical Innovations with regard to Therapeutic Advantage. BMC Clin Pharmacol 2010 Mar 16; 10: 5PubMedCrossRef
18.
Zurück zum Zitat Carlsson P, Jørgensen T. Scanning the horizon for emerging health technologies: conclusions from a European Workshop. Int J Tech Assess Health Care 1998; 14(4): 695–704CrossRef Carlsson P, Jørgensen T. Scanning the horizon for emerging health technologies: conclusions from a European Workshop. Int J Tech Assess Health Care 1998; 14(4): 695–704CrossRef
19.
Zurück zum Zitat Sculpher M, Drummond M, Buxton M. The iterative use of economic evaluation as part of the process of health technology assessment. J Health Serv Res Policy 1997 Jan; 2(1): 26–30PubMed Sculpher M, Drummond M, Buxton M. The iterative use of economic evaluation as part of the process of health technology assessment. J Health Serv Res Policy 1997 Jan; 2(1): 26–30PubMed
20.
Zurück zum Zitat Vallejo-Torres L, Steuten LMG, Buxton MJ, et al. Integrating health economics modeling in the product development cycle of medical devices: a Bayesian approach. Int J Technol Assess Health Care 2008 Oct 3; 24(4): 459–64PubMedCrossRef Vallejo-Torres L, Steuten LMG, Buxton MJ, et al. Integrating health economics modeling in the product development cycle of medical devices: a Bayesian approach. Int J Technol Assess Health Care 2008 Oct 3; 24(4): 459–64PubMedCrossRef
21.
Zurück zum Zitat Vallejo-Torres L, Steuten L, Parkinson B, et al. Integrating health economics into the product development cycle: a case study of absorbable pins for treating hallux valgus. Med Decis Making. Epub 2010 Dec 2 Vallejo-Torres L, Steuten L, Parkinson B, et al. Integrating health economics into the product development cycle: a case study of absorbable pins for treating hallux valgus. Med Decis Making. Epub 2010 Dec 2
22.
Zurück zum Zitat Steuten L, Vallejo-Torres L, Bastide P, et al. Analysing uncertainty around costs of innovative medical technologies: the case of fibrin sealant (QUIXIL) for total knee replacement. Health Policy 2009 Jan 1; 89(1): 46–57PubMedCrossRef Steuten L, Vallejo-Torres L, Bastide P, et al. Analysing uncertainty around costs of innovative medical technologies: the case of fibrin sealant (QUIXIL) for total knee replacement. Health Policy 2009 Jan 1; 89(1): 46–57PubMedCrossRef
23.
Zurück zum Zitat Fenwick E, Palmer S, Claxton K, et al. An iterative Bayesian approach to health technology assessment: application to a policy of preoperative optimization for patients undergoing major elective surgery. Med Decis Making 2006 Sep-Oct; 26(5): 480–96PubMedCrossRef Fenwick E, Palmer S, Claxton K, et al. An iterative Bayesian approach to health technology assessment: application to a policy of preoperative optimization for patients undergoing major elective surgery. Med Decis Making 2006 Sep-Oct; 26(5): 480–96PubMedCrossRef
24.
Zurück zum Zitat Pietzsch JB, Pate-Cornell ME. Early technology assessment of new medical devices. Int J Technol Assess Health Care 2008; 24(1): 36–44PubMedCrossRef Pietzsch JB, Pate-Cornell ME. Early technology assessment of new medical devices. Int J Technol Assess Health Care 2008; 24(1): 36–44PubMedCrossRef
25.
Zurück zum Zitat Kim WJ, Lee JD, Kim TY. Demand forecasting for multi-generational products combining discrete choice and dynamics of diffusion under technological trajectories. Technol Forecast Soc Change 2005 Jan 1; 72: 25CrossRef Kim WJ, Lee JD, Kim TY. Demand forecasting for multi-generational products combining discrete choice and dynamics of diffusion under technological trajectories. Technol Forecast Soc Change 2005 Jan 1; 72: 25CrossRef
26.
Zurück zum Zitat Masum H, Ranck J, Singer PA. Five promising methods for health foresight. Foresight 2010 Jan 1; 12(1): 54–66CrossRef Masum H, Ranck J, Singer PA. Five promising methods for health foresight. Foresight 2010 Jan 1; 12(1): 54–66CrossRef
27.
Zurück zum Zitat Rogers MJ, Gupta A, Maranas CD. Real options based analysis of optimal pharmaceutical research and development portfolios. Ind Eng Chem Res 2002; 41(25): 6607–20CrossRef Rogers MJ, Gupta A, Maranas CD. Real options based analysis of optimal pharmaceutical research and development portfolios. Ind Eng Chem Res 2002; 41(25): 6607–20CrossRef
28.
Zurück zum Zitat Gelijns A, Rosenberg N. The dynamics of technological change in medicine. Health Aff (Millwood) 1994; 13(3): 28–46CrossRef Gelijns A, Rosenberg N. The dynamics of technological change in medicine. Health Aff (Millwood) 1994; 13(3): 28–46CrossRef
29.
Zurück zum Zitat Schot J, Rip A. The past and future of constructive technology assessment. Technol Forecast Soc Change 1997 Apr; 54(2-3): 251–68CrossRef Schot J, Rip A. The past and future of constructive technology assessment. Technol Forecast Soc Change 1997 Apr; 54(2-3): 251–68CrossRef
30.
Zurück zum Zitat Guston D. Real-time technology assessment. Technol Soc 2002; 24(1-2): 93–109CrossRef Guston D. Real-time technology assessment. Technol Soc 2002; 24(1-2): 93–109CrossRef
31.
Zurück zum Zitat Phaal R, Farrukh CJP, Probert DR. Technology road-mapping: a planning framework for evolution and revolution. Technol Forecast Soc Change 2004 Jan 1; 71: 5–26CrossRef Phaal R, Farrukh CJP, Probert DR. Technology road-mapping: a planning framework for evolution and revolution. Technol Forecast Soc Change 2004 Jan 1; 71: 5–26CrossRef
32.
Zurück zum Zitat Shaw B. Innovation and new product development in the UK medical equipment industry. Int J Technol Manage 1998; 15(3/4/5): 433–45CrossRef Shaw B. Innovation and new product development in the UK medical equipment industry. Int J Technol Manage 1998; 15(3/4/5): 433–45CrossRef
33.
Zurück zum Zitat Cosh E, Girling A, Lilford R, et al. Investing in new medical technologies: a decision framework. J Commercial Biotechnol 2007 Aug; 13(4): 263–71CrossRef Cosh E, Girling A, Lilford R, et al. Investing in new medical technologies: a decision framework. J Commercial Biotechnol 2007 Aug; 13(4): 263–71CrossRef
34.
Zurück zum Zitat Zenios S, Makower J, Yock P, et al. Biodesign: the process of innovating medical technologies. 1st ed. Cambridge: Cambridge University Press, 2009CrossRef Zenios S, Makower J, Yock P, et al. Biodesign: the process of innovating medical technologies. 1st ed. Cambridge: Cambridge University Press, 2009CrossRef
35.
Zurück zum Zitat Grant J, Cottrell R, Cluzeau F, et al. Evaluating ‘payback’ on biomedical research from papers cited in clinical guidelines: applied bibliometric study. BMJ 2000; 320(7242): 1107–11PubMedCrossRef Grant J, Cottrell R, Cluzeau F, et al. Evaluating ‘payback’ on biomedical research from papers cited in clinical guidelines: applied bibliometric study. BMJ 2000; 320(7242): 1107–11PubMedCrossRef
36.
Zurück zum Zitat Mindell JS, Boltong A, Forde I. A review of health impact assessment frameworks. Public Health 2008 Nov 1; 122(11): 1177–87PubMedCrossRef Mindell JS, Boltong A, Forde I. A review of health impact assessment frameworks. Public Health 2008 Nov 1; 122(11): 1177–87PubMedCrossRef
37.
Zurück zum Zitat Saaty TL. The analytic hierarchy process: planning, priority setting and resource allocation. London: McGraw Hill International Ltd, 1980 Saaty TL. The analytic hierarchy process: planning, priority setting and resource allocation. London: McGraw Hill International Ltd, 1980
38.
Zurück zum Zitat Lancsar E, Louviere J. Conducting discrete choice experiments to inform healthcare decision making: a user’s guide. Pharmacoeconomics 2008; 26(8): 661–77PubMedCrossRef Lancsar E, Louviere J. Conducting discrete choice experiments to inform healthcare decision making: a user’s guide. Pharmacoeconomics 2008; 26(8): 661–77PubMedCrossRef
39.
Zurück zum Zitat Ryan M, Gerard K, Amaya-Amaya M. Using discrete choice experiments to value health and health care. Dordrecht: Springer, 2008CrossRef Ryan M, Gerard K, Amaya-Amaya M. Using discrete choice experiments to value health and health care. Dordrecht: Springer, 2008CrossRef
40.
Zurück zum Zitat Hartmann M, Hassan A. Application of real options analysis for pharmaceutical R&D project valuation: empirical results from a survey. Res Policy 2006 Jan 1; 35: 343–54CrossRef Hartmann M, Hassan A. Application of real options analysis for pharmaceutical R&D project valuation: empirical results from a survey. Res Policy 2006 Jan 1; 35: 343–54CrossRef
41.
Zurück zum Zitat Douw K, Vondeling H. Selection of new health technologies for assessment aimed at informing decision making: a survey among horizon scanning systems. Int J Technol Assess Health Care 2006 Mar 31; 22(2): 177–83PubMedCrossRef Douw K, Vondeling H. Selection of new health technologies for assessment aimed at informing decision making: a survey among horizon scanning systems. Int J Technol Assess Health Care 2006 Mar 31; 22(2): 177–83PubMedCrossRef
42.
Zurück zum Zitat Holford N, Ma SC, Ploeger BA. Clinical trial simulation: a review. Clin Pharmacol Ther 2010 Jul 1; 88(2): 166–82PubMedCrossRef Holford N, Ma SC, Ploeger BA. Clinical trial simulation: a review. Clin Pharmacol Ther 2010 Jul 1; 88(2): 166–82PubMedCrossRef
43.
Zurück zum Zitat Claxton K, Sculpher M, Drummond M. A rational framework for decision making by the National Institute For Clinical Excellence (NICE). Lancet 2002 Aug 31; 360(9334): 711–5PubMedCrossRef Claxton K, Sculpher M, Drummond M. A rational framework for decision making by the National Institute For Clinical Excellence (NICE). Lancet 2002 Aug 31; 360(9334): 711–5PubMedCrossRef
44.
Zurück zum Zitat Chalmers I. Evaluating ‘payback’ on biomedical research: biomedical funding decisions should be audited. BMJ 2000; 321(7260): 566PubMedCrossRef Chalmers I. Evaluating ‘payback’ on biomedical research: biomedical funding decisions should be audited. BMJ 2000; 321(7260): 566PubMedCrossRef
45.
Zurück zum Zitat Hanney SR, Gonzalez Block MA. Building health research systems to achieve better health. Health Res Policy Syst 2006; 4(10): 6 Hanney SR, Gonzalez Block MA. Building health research systems to achieve better health. Health Res Policy Syst 2006; 4(10): 6
46.
Zurück zum Zitat Yazdizadeh B, Majdzadeh R, Salmasian H. Systematic review of methods for evaluating healthcare research economic impact. Health Res Policy Syst 2010 Jan 1; 8: 6PubMedCrossRef Yazdizadeh B, Majdzadeh R, Salmasian H. Systematic review of methods for evaluating healthcare research economic impact. Health Res Policy Syst 2010 Jan 1; 8: 6PubMedCrossRef
47.
Zurück zum Zitat Reed SD, Shea AM, Schulman KA. Economic implications of potential changes to regulatory and reimbursement policies for medical devices. J Gen Intern Med 2008 Jan 1; 23 Suppl. 1: 50–6CrossRef Reed SD, Shea AM, Schulman KA. Economic implications of potential changes to regulatory and reimbursement policies for medical devices. J Gen Intern Med 2008 Jan 1; 23 Suppl. 1: 50–6CrossRef
48.
Zurück zum Zitat Hummel JM, van Rossum W, Verkerke GJ, et al. Medical technology assessment: the use of the analytic hierarchy process as a tool for multidisciplinary evaluation of medical devices. Int J Artif Organs 2000 Nov; 23(11): 782–7PubMed Hummel JM, van Rossum W, Verkerke GJ, et al. Medical technology assessment: the use of the analytic hierarchy process as a tool for multidisciplinary evaluation of medical devices. Int J Artif Organs 2000 Nov; 23(11): 782–7PubMed
49.
Zurück zum Zitat Sloane E, Liberatore M, Nydick R, et al. Using the analytic hierarchy process as a clinical engineering tool to facilitate an iterative, multidisciplinary, microeconomic health technology assessment. Comput Oper Res 2003; 1447–65 Sloane E, Liberatore M, Nydick R, et al. Using the analytic hierarchy process as a clinical engineering tool to facilitate an iterative, multidisciplinary, microeconomic health technology assessment. Comput Oper Res 2003; 1447–65
50.
Zurück zum Zitat Hummel JM, Ijzerman MJ. The use of the analytic hierarchy process in health care decision making. Health Sciences Series. Enschede: Health Technology & Services Research, 2009 Hummel JM, Ijzerman MJ. The use of the analytic hierarchy process in health care decision making. Health Sciences Series. Enschede: Health Technology & Services Research, 2009
51.
Zurück zum Zitat Kallas Z, Lambarraa F, Gil JM. A stated preference analysis comparing the analytical hierarchy process versus choice experiments. Food Qual Pref 2011; 22(2): 181–92CrossRef Kallas Z, Lambarraa F, Gil JM. A stated preference analysis comparing the analytical hierarchy process versus choice experiments. Food Qual Pref 2011; 22(2): 181–92CrossRef
52.
Zurück zum Zitat Mulye R. An empirical comparison of three variants of the AHP and two variants of conjoint analysis. J Behavioral Decision Making 1998; 11: 263–80CrossRef Mulye R. An empirical comparison of three variants of the AHP and two variants of conjoint analysis. J Behavioral Decision Making 1998; 11: 263–80CrossRef
53.
Zurück zum Zitat Ijzerman MJ, Bridges JF, van Til JA. A comparison of analytical hierarchical process and conjoint analysis methods in assessing treatment alternatives for stroke rehabilitation. Patient. In press Ijzerman MJ, Bridges JF, van Til JA. A comparison of analytical hierarchical process and conjoint analysis methods in assessing treatment alternatives for stroke rehabilitation. Patient. In press
54.
Zurück zum Zitat Johnson FR, Mohamed AF, Ozdemir S, et al. How does cost matter in health-care discrete-choice experiments? Health Econ 2011 Apr; 20(3): 323–30PubMedCrossRef Johnson FR, Mohamed AF, Ozdemir S, et al. How does cost matter in health-care discrete-choice experiments? Health Econ 2011 Apr; 20(3): 323–30PubMedCrossRef
55.
Zurück zum Zitat Lynd LD, Najafzadeh M, Colley L, et al. Using the incremental net benefit framework for quantitative benefit-risk analysis in regulatory decision-making: a case study of alosetron in irritable bowel syndrome. Value Health 2010 Jun; 13(4): 411–7PubMedCrossRef Lynd LD, Najafzadeh M, Colley L, et al. Using the incremental net benefit framework for quantitative benefit-risk analysis in regulatory decision-making: a case study of alosetron in irritable bowel syndrome. Value Health 2010 Jun; 13(4): 411–7PubMedCrossRef
56.
Zurück zum Zitat Sanders PMH, Ijzerman MJ, Roach MJ, et al. Patient preferences for next generation neural prostheses to restore bladder function. Spinal Cord 2011 Jun 8; 49(1): 113–9PubMedCrossRef Sanders PMH, Ijzerman MJ, Roach MJ, et al. Patient preferences for next generation neural prostheses to restore bladder function. Spinal Cord 2011 Jun 8; 49(1): 113–9PubMedCrossRef
57.
Zurück zum Zitat van Til JA, Renzenbrink GJ, Groothuis K, et al. A preliminary economic evaluation of percutaneous neuromuscular electrical stimulation in the treatment of hemiplegic shoulder pain. Disabil Rehabil 2006 May 30; 28(10): 645–51PubMedCrossRef van Til JA, Renzenbrink GJ, Groothuis K, et al. A preliminary economic evaluation of percutaneous neuromuscular electrical stimulation in the treatment of hemiplegic shoulder pain. Disabil Rehabil 2006 May 30; 28(10): 645–51PubMedCrossRef
58.
Zurück zum Zitat Girling A, Young T, Brown C, et al. Early-stage valuation of medical devices: the role of developmental uncertainty. Value Health 2010 Aug 1; 13(5): 585–91PubMedCrossRef Girling A, Young T, Brown C, et al. Early-stage valuation of medical devices: the role of developmental uncertainty. Value Health 2010 Aug 1; 13(5): 585–91PubMedCrossRef
59.
Zurück zum Zitat McAteer H, Cosh E, Freeman G, et al. Cost-effectiveness analysis at the development phase of a potential health technology: examples based on tissue engineering of bladder and urethra. J Tissue Eng Regen Med 2007 Sep-Oct; 1(5): 343–9PubMedCrossRef McAteer H, Cosh E, Freeman G, et al. Cost-effectiveness analysis at the development phase of a potential health technology: examples based on tissue engineering of bladder and urethra. J Tissue Eng Regen Med 2007 Sep-Oct; 1(5): 343–9PubMedCrossRef
60.
Zurück zum Zitat Buurman J, Zhang S, Babovic V. Reducing risk through real options in systems design: the case of architecting a maritime domain protection system. Risk Anal 2009 Mar 1; 29(3): 366–79PubMedCrossRef Buurman J, Zhang S, Babovic V. Reducing risk through real options in systems design: the case of architecting a maritime domain protection system. Risk Anal 2009 Mar 1; 29(3): 366–79PubMedCrossRef
61.
Zurück zum Zitat Mun J. Real options analysis: tools and techniques for valuing strategic investments and decisions. 2nd ed. Hoboken (NJ): John Wiley & Sons, 2006: xxxi, 667 Mun J. Real options analysis: tools and techniques for valuing strategic investments and decisions. 2nd ed. Hoboken (NJ): John Wiley & Sons, 2006: xxxi, 667
62.
Zurück zum Zitat Smith JE, Nau RF. Valuing risky projects: option pricing theory and decision analysis. Manage Sci 1995; 41(5): 795–816CrossRef Smith JE, Nau RF. Valuing risky projects: option pricing theory and decision analysis. Manage Sci 1995; 41(5): 795–816CrossRef
63.
Zurück zum Zitat Pertile P, Torri E, Flor L, et al. The timing of adoption of positron emission tomography: a real options approach. Health Care Manag Sci 2009 Sep 1; 12(3): 217–27PubMedCrossRef Pertile P, Torri E, Flor L, et al. The timing of adoption of positron emission tomography: a real options approach. Health Care Manag Sci 2009 Sep 1; 12(3): 217–27PubMedCrossRef
64.
Zurück zum Zitat Attema AE, Lugnér AK, Feenstra TL. Investment in antiviral drugs: a real options approach. Health Econ 2010 Oct 1; 19(10): 1240–54PubMedCrossRef Attema AE, Lugnér AK, Feenstra TL. Investment in antiviral drugs: a real options approach. Health Econ 2010 Oct 1; 19(10): 1240–54PubMedCrossRef
65.
Zurück zum Zitat Driffield T, Smith PC. A real options approach to watchful waiting: theory and an illustration. Med Decis Making 2007 Jan 1; 27(2): 178–88PubMedCrossRef Driffield T, Smith PC. A real options approach to watchful waiting: theory and an illustration. Med Decis Making 2007 Jan 1; 27(2): 178–88PubMedCrossRef
66.
Zurück zum Zitat Kimko HC, Duffull SB. Simulation for designing clinical trials: a pharmacokinetic-pharmacodynamic modeling perspective. New York: Marcel Dekker, 2003 Kimko HC, Duffull SB. Simulation for designing clinical trials: a pharmacokinetic-pharmacodynamic modeling perspective. New York: Marcel Dekker, 2003
67.
Zurück zum Zitat DiMasi JA, Hansen RW, Grabowski HG. The price of innovation: new estimates of drug development costs. J Health Econ 2003 Mar 1; 22(2): 151–85PubMedCrossRef DiMasi JA, Hansen RW, Grabowski HG. The price of innovation: new estimates of drug development costs. J Health Econ 2003 Mar 1; 22(2): 151–85PubMedCrossRef
68.
Zurück zum Zitat De Ridder F. Predicting the outcome of phase III trials using phase II data: a case study of clinical trial simulation in late stage drug development. Basic Clin Pharmacol Toxicol 2005; 96(3): 235–41PubMedCrossRef De Ridder F. Predicting the outcome of phase III trials using phase II data: a case study of clinical trial simulation in late stage drug development. Basic Clin Pharmacol Toxicol 2005; 96(3): 235–41PubMedCrossRef
69.
Zurück zum Zitat Volosin KJ, Exner DV, Wathen MS, et al. Combining shock reduction strategies to enhance ICD therapy: a role for computer modeling. J Cardiovasc Electrophysiol 2011 Mar; 22(3): 280–9PubMedCrossRef Volosin KJ, Exner DV, Wathen MS, et al. Combining shock reduction strategies to enhance ICD therapy: a role for computer modeling. J Cardiovasc Electrophysiol 2011 Mar; 22(3): 280–9PubMedCrossRef
70.
Zurück zum Zitat Pibouleau L, Chevret S. Bayesian statistical method was underused despite its advantages in the assessment of implantable medical devices. J Clin Epidemiol 2011 Mar; 64(3): 270–9PubMedCrossRef Pibouleau L, Chevret S. Bayesian statistical method was underused despite its advantages in the assessment of implantable medical devices. J Clin Epidemiol 2011 Mar; 64(3): 270–9PubMedCrossRef
71.
Zurück zum Zitat Retèl VP, Hummel MJM, van Harten WH. Review on early technology assessments of nanotechnologies in oncology. Mol Oncol 2009 Dec 1; 3(5-6): 394–401PubMedCrossRef Retèl VP, Hummel MJM, van Harten WH. Review on early technology assessments of nanotechnologies in oncology. Mol Oncol 2009 Dec 1; 3(5-6): 394–401PubMedCrossRef
72.
Zurück zum Zitat Sculpher M, Claxton K. Establishing the cost-effectiveness of new pharmaceuticals under conditions of uncertainty: when is there sufficient evidence? Value Health 2005 Jan 1; 8(4): 433–46PubMedCrossRef Sculpher M, Claxton K. Establishing the cost-effectiveness of new pharmaceuticals under conditions of uncertainty: when is there sufficient evidence? Value Health 2005 Jan 1; 8(4): 433–46PubMedCrossRef
73.
Zurück zum Zitat Claxton KP, Sculpher MJ. Using value of information analysis to prioritise health research: some lessons from recent UK experience. Pharmacoeconomics 2006; 24(11): 1055–68PubMedCrossRef Claxton KP, Sculpher MJ. Using value of information analysis to prioritise health research: some lessons from recent UK experience. Pharmacoeconomics 2006; 24(11): 1055–68PubMedCrossRef
74.
Zurück zum Zitat Fenwick E, Claxton K, Sculpher M. The value of implementation and the value of information: combined and uneven development. Med Decis Making 2008 Jan 1; 28(1): 21–32PubMedCrossRef Fenwick E, Claxton K, Sculpher M. The value of implementation and the value of information: combined and uneven development. Med Decis Making 2008 Jan 1; 28(1): 21–32PubMedCrossRef
75.
Zurück zum Zitat Bojke L, Claxton K, Sculpher M, et al. Characterizing structural uncertainty in decision analytic models: a review and application of methods. Value Health 2008 Dec 9; 12(5): 739–49CrossRef Bojke L, Claxton K, Sculpher M, et al. Characterizing structural uncertainty in decision analytic models: a review and application of methods. Value Health 2008 Dec 9; 12(5): 739–49CrossRef
76.
Zurück zum Zitat Groot Koerkamp B, Stijnen T, Weinstein MC, et al. The combined analysis of uncertainty and patient heterogeneity in medical decision models. Med Decis Making. Epub 2010 Oct 25 Groot Koerkamp B, Stijnen T, Weinstein MC, et al. The combined analysis of uncertainty and patient heterogeneity in medical decision models. Med Decis Making. Epub 2010 Oct 25
77.
Zurück zum Zitat O’Hagan A, McCabe C, Akehurst R, et al. Incorporation of uncertainty in health economic modelling studies. Pharmacoeconomics 2005; 23(6): 529–36PubMedCrossRef O’Hagan A, McCabe C, Akehurst R, et al. Incorporation of uncertainty in health economic modelling studies. Pharmacoeconomics 2005; 23(6): 529–36PubMedCrossRef
78.
Zurück zum Zitat O’Hagan A. Eliciting expert beliefs in substantial practical applications. Statistician 1998 Jan 1; 47(1): 21–35 O’Hagan A. Eliciting expert beliefs in substantial practical applications. Statistician 1998 Jan 1; 47(1): 21–35
79.
Zurück zum Zitat Garthwaite PH, Kadane J, O’Hagan A. Statistical methods for eliciting probability distributions. J Am Stat Assoc 2005 Jan 1; 100(470): 680–701CrossRef Garthwaite PH, Kadane J, O’Hagan A. Statistical methods for eliciting probability distributions. J Am Stat Assoc 2005 Jan 1; 100(470): 680–701CrossRef
80.
Zurück zum Zitat Johnson SR, Tomlinson GA, Hawker GA, et al. Methods to elicit beliefs for Bayesian priors: a systematic review. J Clin Epidemiol 2010 Apr 1; 63(4): 355–69PubMedCrossRef Johnson SR, Tomlinson GA, Hawker GA, et al. Methods to elicit beliefs for Bayesian priors: a systematic review. J Clin Epidemiol 2010 Apr 1; 63(4): 355–69PubMedCrossRef
81.
Zurück zum Zitat Johnson SR, Tomlinson GA, Hawker GA, et al. A valid and reliable belief elicitation method for Bayesian priors. J Clin Epidemiol 2010 Apr 1; 63(4): 370–83PubMedCrossRef Johnson SR, Tomlinson GA, Hawker GA, et al. A valid and reliable belief elicitation method for Bayesian priors. J Clin Epidemiol 2010 Apr 1; 63(4): 370–83PubMedCrossRef
82.
Zurück zum Zitat Bojke L, Claxton K, Bravo-Vergel Y, et al. Eliciting distributions to populate decision analytic models. Value Health 2010 Jul 1; 13(5): 557–64PubMedCrossRef Bojke L, Claxton K, Bravo-Vergel Y, et al. Eliciting distributions to populate decision analytic models. Value Health 2010 Jul 1; 13(5): 557–64PubMedCrossRef
83.
Zurück zum Zitat Hilgerink MP, Hummel JM, Manohar S, et al. Assessment of the added value of the Twente Photoacoustic Mammoscope in breast cancer diagnosis. Med Devices Evid Res 2011; 4: 107–15CrossRef Hilgerink MP, Hummel JM, Manohar S, et al. Assessment of the added value of the Twente Photoacoustic Mammoscope in breast cancer diagnosis. Med Devices Evid Res 2011; 4: 107–15CrossRef
84.
Zurück zum Zitat Steuten LMG, Hummel JM, Groothuis-Oudshoorn CGB, et al. Using AHP weights to fill missing gaps in Markov decision models. Value Health 2010; 13(7): A241CrossRef Steuten LMG, Hummel JM, Groothuis-Oudshoorn CGB, et al. Using AHP weights to fill missing gaps in Markov decision models. Value Health 2010; 13(7): A241CrossRef
85.
Zurück zum Zitat Martino J. A review of selected recent advances in technological forecasting. Technol Forecast Soc Change 2003 Jan 1; 70: 719–33CrossRef Martino J. A review of selected recent advances in technological forecasting. Technol Forecast Soc Change 2003 Jan 1; 70: 719–33CrossRef
86.
Zurück zum Zitat Huang L, Guo Y, Porter AL. A systematic technology forecasting approach for new and emerging science and technology: case study of nano-enhanced biosensors. Atlanta Conference on Science Innovation Policy; 2009 Oct 2-3; Atlanta (GA) Huang L, Guo Y, Porter AL. A systematic technology forecasting approach for new and emerging science and technology: case study of nano-enhanced biosensors. Atlanta Conference on Science Innovation Policy; 2009 Oct 2-3; Atlanta (GA)
87.
Zurück zum Zitat Bridges JF, Buttorff C. What outcomes should US policy makers compare in comparative effectiveness research? Expert Rev Pharmacoecon Outcomes Res 2010 Jun; 10(3): 217–20PubMedCrossRef Bridges JF, Buttorff C. What outcomes should US policy makers compare in comparative effectiveness research? Expert Rev Pharmacoecon Outcomes Res 2010 Jun; 10(3): 217–20PubMedCrossRef
88.
Zurück zum Zitat Facey K, Boivin A, Gracia J, et al. Patients’ perspectives in health technology assessment: a route to robust evidence and fair deliberation. Int J Technol Assess Health Care 2010 Jul; 26(3): 334–40PubMedCrossRef Facey K, Boivin A, Gracia J, et al. Patients’ perspectives in health technology assessment: a route to robust evidence and fair deliberation. Int J Technol Assess Health Care 2010 Jul; 26(3): 334–40PubMedCrossRef
89.
Zurück zum Zitat Brazier J, Akehurst R, Brennan A, et al. Should patients have a greater role in valuing health states? Appl Health Econ Health Policy 2005 Jan 1; 4(4): 201–8PubMedCrossRef Brazier J, Akehurst R, Brennan A, et al. Should patients have a greater role in valuing health states? Appl Health Econ Health Policy 2005 Jan 1; 4(4): 201–8PubMedCrossRef
90.
Zurück zum Zitat Gezondheidsraad. Medical products: new and needed! An investment strategy for research into innovative and relevant medical products. The Hague: Health Council of the Netherlands, 2011. Publication no. 2011/01 Gezondheidsraad. Medical products: new and needed! An investment strategy for research into innovative and relevant medical products. The Hague: Health Council of the Netherlands, 2011. Publication no. 2011/01
91.
Zurück zum Zitat Lettl C, Herstatt C, Gemuenden HG. Users’ contributions to radical innovation: evidence from four cases in the field of medical equipment technology. R&D Manage 2006 Jan 1; 36(3): 251–72CrossRef Lettl C, Herstatt C, Gemuenden HG. Users’ contributions to radical innovation: evidence from four cases in the field of medical equipment technology. R&D Manage 2006 Jan 1; 36(3): 251–72CrossRef
92.
Zurück zum Zitat Snoek GJ, van Til JA, Krabbe PF, et al. Decision for reconstructive interventions of the upper limb in individuals with tetraplegia: the effect of treatment characteristics. Spinal Cord 2008 Mar; 46(3): 228–33PubMedCrossRef Snoek GJ, van Til JA, Krabbe PF, et al. Decision for reconstructive interventions of the upper limb in individuals with tetraplegia: the effect of treatment characteristics. Spinal Cord 2008 Mar; 46(3): 228–33PubMedCrossRef
93.
Zurück zum Zitat Lloyd A, Swinburn P, Boye KS, et al. A valuation of infusion therapy to preserve islet function in type 1 diabetes. Value Health 2010 Aug 1; 13(5): 636–42PubMedCrossRef Lloyd A, Swinburn P, Boye KS, et al. A valuation of infusion therapy to preserve islet function in type 1 diabetes. Value Health 2010 Aug 1; 13(5): 636–42PubMedCrossRef
Metadaten
Titel
Early assessment of medical technologies to inform product development and market access
A review of methods and applications
verfasst von
Dr Maarten J. Ijzerman
Lotte M. G. Steuten
Publikationsdatum
01.09.2011
Verlag
Springer International Publishing
Erschienen in
Applied Health Economics and Health Policy / Ausgabe 5/2011
Print ISSN: 1175-5652
Elektronische ISSN: 1179-1896
DOI
https://doi.org/10.2165/11593380-000000000-00000

Weitere Artikel der Ausgabe 5/2011

Applied Health Economics and Health Policy 5/2011 Zur Ausgabe